Keyphrases
Adipose-derived Stromal Cells
100%
Allogeneic
56%
Cryopreserved
32%
Ischemic Heart Failure
31%
Mesenchymal Stromal Cells
24%
Left Ventricular End-diastolic Volume (LVEDV)
24%
Angiogenesis
23%
Heart Failure with Preserved Ejection Fraction (HFpEF)
22%
Cellular Products
20%
Juxtacrine
19%
Ischemic Heart Disease
19%
Paracrine
19%
Stem Cells
17%
Cardiology
16%
Rat Model
14%
Left Ventricular Ejection Fraction
14%
Intramyocardial Injection
13%
Chronic Ischemic Heart Failure
13%
Between-group
12%
Phase II Trial
12%
Patients with Chronic Heart Failure
11%
Cell Treatment
11%
6-month Follow-up
10%
Placebo
10%
Fibroblasts
10%
Healthy Donors
10%
Triple Cell Co-culture
9%
Growth Factor Therapy
9%
Stromal Cell Therapy
9%
Chronic Ischemic Cardiomyopathy
9%
Macromolecular Crowding
9%
Hypoxia
9%
School-based
9%
Cardiac Tissue
9%
Good Manufacturing Practice
9%
Senescence
9%
Heart Failure
9%
Fetal Bovine Serum
9%
Preventive Intervention
9%
Alginate Hydrogel
9%
Co-culture Model
9%
Potency Assay
9%
Acute Myocardial Infarction
9%
Safety Study
9%
Smoking Prevention
9%
Functional Impact
9%
Collagen
9%
Clinical Application
9%
Gene Transcription
9%
Tissue Response
9%
Medicine and Dentistry
Adipose Tissue
50%
Heart Failure
41%
Heart Muscle Ischemia
41%
Mesenchymal Stem Cell
30%
Stromal Cell
29%
Placebo
27%
Heart Left Ventricle Ejection Fraction
27%
Ischemic Heart Disease
19%
End-Systolic Volume
18%
Stem Cell
16%
Cell Therapy
16%
Cardiology
15%
Phase II Trials
12%
New York Heart Association Class
11%
Adverse Event
11%
Myocardium
10%
Heart Failure with Reduced Ejection Fraction
9%
Vasculotropin
9%
Symptom
8%
Six Minute Walk Test
7%
End-Diastolic Volume
7%
Heart Function
7%
Quality of Life
7%
Care Group
5%
